アザシチジンと組み合わせたAPR-246の安全性と有効性の研究
変異TP53(TP53)変異骨髄性新生物の治療のためのアザシチジンと組み合わせたAPR-246の安全性と有効性を評価する第1b / 2相試験
The main purpose of this study is to determine the safe and efficacy of APR-246 in combination with azacitidine as well as to see complete remission of this patients
調査の概要
詳細な説明
Patients will be treated for a total of 6 cycles.For patients responding or who have stable disease following cycle 6, treatment may continue until one of the following criteria applies:
- Inter-current illness that prevent further administration of treatment
- Unacceptable adverse event(s)
- Participant decides to withdraw from the study,
- general or specific changes in the participant's condition render the participant unacceptable for further treatment in the judgment of the investigator.
- Evidence of disease progression by international working Group (IWG) 2006 criteria.
- participants who wish not to continue treatment at time of disease assessment at end of cycle 6 will complete their end of treatment visit upon completion of cycle 6
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Lille、フランス、59037
- Bruno Quesnel
-
Nantes、フランス、44093
- Dr Pierre Peterlin and Pr Patrice Chevalier
-
Nice、フランス、06200
- Hôpital Archet 1
-
Paris、フランス、75010
- Hôpital Saint Louis - Hématologie Séniors
-
Paris、フランス、75679
- Hôpital Cochin/Service d'Hématologie
-
Rouen、フランス、76038
- Aspasia Stamatoullas
-
Toulouse、フランス、31059
- Odile Beyne Rosy
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.
-
Patient has adequate organ function as defined by the following laboratory values:
- Serum creatinine ≤ 2 x upper limit of normal (ULN)
- Total serum bilirubin < 1.5 x ULN or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome or hemolysis or who required regular blood transfusions
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
-
Age ≥18 years at the time of signing the informed consent form
-
Documented diagnosis of myelodysplastic syndrome (MDS), MDS/ myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML) by World Health organization (WHO) criteria or non-proliferative AML (ie with WBC < 20 G/l)
-
Documentation of a TP53 gene mutation by next-generation sequencing (NGS) based on central or local evaluation.
-
Revised International Prognostic Scoring System (IPSS-R) criteria for Intermediate, High-risk or Very High-risk.
-
An Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 is required.
-
If of childbearing potential, negative pre-treatment urine or serum pregnancy test.
-
If of childbearing potential (males and females), willing to use an effective form of contraception such as latex condom, hormonal birth control, intrauterine device or double barrier method during chemotherapy treatment and for at least six months thereafter.
Exclusion Criteria:
-
Patient has a known history of HIV or active hepatitis B or active hepatitis C infection (testing not mandatory).
-
Patient has any of the following cardiac abnormalities (as determined by treating MD):
- symptomatic congestive heart failure
- myocardial infarction ≤ 6 months prior to enrollment
- unstable angina pectoris
- serious uncontrolled cardiac arrhythmia
- QTc ≥ 470 msec (≥ 500 msec in the presence of RBBB) calculated from a mean of 3 ECG readings using Fridericia's correction (QTcF = QT/RR0.33)
- bradycardia (<40 bpm)
- known left ventricular ejection fraction (LVEF) < the institution lower limit of normal as assessed by ECHO
- clinically significant pericardial disease
- electrocardiographic evidence of acute ischemia
- familial history of long QT syndrome
-
Concomitant malignancies or previous malignancies with less than a 1-year disease free interval at the time of signing consent. Patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis.
-
Prior exposure to azacitidine, decitabine or investigational hypomethylating agent
-
Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of MDS, MDS/MPN, CMML or AML within 14 days of the first day of study drug treatment.
-
No concurrent use of erythroid stimulating agents, Granulocyte-colony stimulating Factor (G-CSF), Granulocyte Macrophage-colony stimulating factor (GM-CSF) is allowed during study except in cases of febrile neutropenia where G-CSF can be used for short term. Growth factors must be stopped 14 days prior to study.
-
Patients with history of allogeneic stem cell transplantation.
-
Pregnant women are excluded from this study because APR-246 has not been studied in pregnant subjects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with APR-246, breastfeeding should be discontinued if the mother is treated with APR-246.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:combination of APR246 and azacitidine
Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b |
Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
他の名前:
azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival
時間枠:8 months
|
overall survival at complete remission |
8 months
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
応答時間
時間枠:少なくとも 24 か月は、反応が達成されてから疾患が進行するまでの時間として定義されます。
|
少なくとも 24 か月は、反応が達成されてから疾患が進行するまでの時間として定義されます。
|
協力者と研究者
捜査官
- 主任研究者:Pierre Fenaux、service Hématologie Séniors Hôpital Saint Louis
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- GFM-APR246
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。